greeksoup/ stock research
Stock research / United States / ZBIO / Filings

Zenas BioPharma, Inc. SEC filings

Zenas BioPharma filed 20 documents with the SEC in the last twelve months, the latest report being the 10-Q of 13 August 2026. The latest filing, on 13 October 2026, was an 8-K: regulation fd disclosure.

Filings in twelve months209 of them 8-K news
Latest report10-Qfiled 13 Aug 2026
Latest filing8-K13 Oct 2026
Last results, two-day move-5.7%results filed 13 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were proxy and other (7). Results came out 5 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 5 releases the share price moved 13.3% on average in the two days around results, the most on 5 Jan 2026 (-55.9%).

5 Jan 2026-55.9%$34.50 to $15.20
16 Mar 2026-2.3%$24.04 to $23.48
13 May 2026-1.4%$19.16 to $18.90
13 Aug 2026-5.7%$31.29 to $29.51
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

9 filings

Zenas BioPharma's 9 news filings (8-K) were mostly about results of operations (5) and officer or director change (4).

  • Results of operationsThe quarterly results release
    5 · latest 13 Aug 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    4 · latest 13 Aug 2026
  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    2 · latest 13 Oct 2026
  • Other eventsNews the company chose to file
    2 · latest 31 Mar 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 13 May 2026
  • Material agreementA large contract or deal was signed
    1 · latest 31 Mar 2026
  • New financial obligationNew debt or a borrowing
    1 · latest 31 Mar 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Zenas BioPharma, Inc. filed 20 documents with the SEC of the kinds listed here: 9 current reports (8-K), about 5 results of operations; 4 officer or director change; 2 regulation FD disclosure; 2 other events; 1 shareholder vote; 3 employee share plan registrations (S-8), 3 quarterly reports (10-Q), 1 shelf registration (S-3ASR), 1 additional proxy material (DEFA14A), 1 annual report to shareholders (ARS), 1 proxy statement (DEF 14A). The latest, filed 13 October 2026: 8-K, regulation FD disclosure. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    13 October 20268-KRegulation FD disclosure12 October 2026EDGAR
    11 September 2026S-3ASRshelf registrationEDGAR
    11 September 2026S-8employee share plan registrationEDGAR
    13 August 202610-Qquarterly report30 June 2026EDGAR
    13 August 20268-KResults of operations, Officer or director change12 August 2026EDGAR
    13 May 202610-Qquarterly report31 March 2026EDGAR
    13 May 20268-KResults of operations, Officer or director change, Shareholder vote11 May 2026EDGAR
    31 March 20268-KMaterial agreement, New financial obligation, Other events26 March 2026EDGAR
    16 March 2026DEFA14Aadditional proxy materialEDGAR
    16 March 2026ARSannual report to shareholders31 December 2025EDGAR
    16 March 2026DEF 14Aproxy statement11 May 2026EDGAR
    16 March 2026S-8employee share plan registrationEDGAR
    16 March 202610-Kannual report31 December 2025EDGAR
    16 March 20268-KResults of operations16 March 2026EDGAR
    13 February 20268-KOfficer or director change10 February 2026EDGAR
    5 January 20268-KResults of operations, Regulation FD disclosure, Other events5 January 2026EDGAR
    19 December 2025S-8employee share plan registrationEDGAR
    15 December 20258-KOfficer or director change10 December 2025EDGAR
    12 November 202510-Qquarterly report30 September 2025EDGAR
    12 November 20258-KResults of operations12 November 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.